Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bayer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rosacea Concierge Program | Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azelaic Acid (Finacea Foam, BAY39-6251) | Drug | Finacea Foam, Active substance Azelaic acid |
|
| Measure | Description | Time Frame |
|---|---|---|
| Demographics and clinical characteristics | Collected patient demographics and characteristics are :
| one-time survey in 2 week recruitment window |
| Rosacea-relevant comorbidities and complications | Patient reported history of the following will be collected :
| one-time survey in 2 week recruitment window |
| Rosacea subtype | Patient reported diagnosis of the following will be collected:
| one-time survey in 2 week recruitment window |
| Past use of topical rosacea treatments | Patient reported use of the following medications will be collected:
| one-time survey in 2 week recruitment window |
| Patient concerns collected by Rosacea Treatment Preference Questionnaire | Rosacea Treatment Preference Questionnaire is a survey to assess patient self-reported rosacea subtype and severity, and to evaluate the concerns that contribute to patient satisfaction/dissatisfaction, as well as treatment decisions with rosacea topical treatments | one-time survey in 2 week recruitment window |
| Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Use of any other topical treatment for rosacea at the time of enrollment
Not provided
Not provided
Not provided
Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xcenda, LLC | Palm Harbor | Florida | 34685 | United States |
Not provided
| ID | Term |
|---|---|
| D012393 | Rosacea |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C010038 | azelaic acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
SATMED-Q is a 17-question, validated, multidimensional generic questionnaire designed for use in patients with any chronic disease treated with medicines
| one-time survey in 2 week recruitment window |
| Quality of life measured by Dermatology Life Quality Index (DLQI) | DLQI is a widely used dermatology-related quality of life tool | one-time survey in 2 week recruitment window |